Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

David T. Yeung, Naranie Shanmuganathan, Timothy P. Hughes

Research output: Contribution to journalEditorialpeer-review

8 Citations (Scopus)


Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.

Original languageEnglish
Pages (from-to)3474-3479
Number of pages6
Issue number24
Publication statusPublished or Issued - 16 Jun 2022

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this